Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Campbell, California (PRWEB) March 31, 2015 ... management consulting firm with operations in California, Oregon, ... formal launch of its Merger and Acquisition (M&A) ... , Peter Adams, VP Client Services and M&A ... repeatedly shown that the vast majority of M&A ...
(Date:3/30/2015)... Calif. , March 30, 2015  NuGene ... its subsidiary corporation, NuGene BioPharma, Inc. has added ... Dr. Guan is an internationally recognized ... finishing his college education at Peking University, ... Ph.D. degree from the University of North Carolina, ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... , March 30, 2015 ... auf    Richmond Pharmacology ist das erste ... Amyloidose-Zentrum am Royal Free Hospital in ... zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten ... von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4
... Cara Therapeutics, Inc.,announced today that it ... funding,to its original $24 million Series C ... was led by new investor, Devon Park ... investors participating,in the round included; Ascent Biomedical ...
... SILVER SPRING, Md., July 24 United,Therapeutics Corporation ... will,release its 2008 second quarter financial results before ... United Therapeutics will host a half-hour teleconference ... Time. The teleconference is accessible,by dialing 1-800-603-1777, with ...
... Agrees to Increase Original Warrant Amount by an Additional ... ... MTA: CTIC) today announced that a single institutional investor,has agreed to purchase, ... conversion price of $0.79 per share, and a,warrant to purchase approximately 28.2 ...
Cached Biology Technology:Cara Therapeutics Secures $12.3 Million in Series C Extension Financing 2Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants 2Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants 3
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... Louis, MO Current research provides a novel model for ... al, "Characterization of the KRN cell transfer model of rheumatoid ... mouse," appears in the September 2010 issue of The ... population is affected by rheumatoid arthritis, and women are affected ...
... University in Washington, D.C., have received a five-year, $3.15 million ... new interdisciplinary program in the environmental affects and policy implications ... ... the Integrative Graduate Education and Research Traineeship (IGERT), which enables ...
... to the slate of expertswhich includes military medical ... Partnerships, on September 23, 2010, at the Omni ... a premier opportunity for representatives of the public ... medical partnerships to benefit our nation,s wounded warriors ...
Cached Biology News:Casing the joint 2Carnegie Mellon receives funding to create new program studying environmental impact of nanotechnology 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 3
... The Finnpipette BioControl multichannel ... features as the single ... handle fits allseven multichannel ... tip cone modules. Both ...
cystatin A (N-18)...
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: